Abstract Details

Title Feasibility of a Home Sleep Apnea Test in a Cognitively Impaired Population

Topic Sleep

Presentation(s) P1 - Poster Session 1 (12:00 PM-1:00 PM)

Poster/Presentation
Number 5-011

Objective To assess if home sleep apnea testing (HSAT) is a clinically feasible approach to screen for obstructive sleep apnea (OSA) in a cognitively impaired patient population.

Background OSA, which causes abnormal pauses in breathing during sleep, increases the risk of developing cognitive impairment. Although in-laboratory polysomnography (PSG) is the gold standard tool to diagnose OSA, it is often underutilized due to long wait times, high costs and patient reluctance to spend a night in a sleep laboratory. HSAT may be a more accessible alternative, as it is simple to use, conveniently administered in a patient’s own home and validated against PSG.

Design/Methods Patients with cognitive impairment due to neurodegenerative and/or vascular etiologies were enrolled and completed various cognitive, sleep, and mood assessments and questionnaires. Patients also completed OSA screening using a HSAT. HSAT was considered a feasible technique if ≥80% of the study population obtained ≥4 hours of analyzable data. HSAT was considered a practical technique if ≥50% of the patients approached obtained ≥4 hours of analyzable data.

Results One hundred and seventeen eligible patients were approached for participation, eighty-one completed the baseline assessment and seventy-six patients completed baseline testing and attempted HSAT. Patients who attempted HSAT had a mean age (±SD) of 72.0 (±11.2) years, 44.7% identified as male and the median Montreal Cognitive Assessment score was 22. Ninety-two percent (70/76) of patients obtained ≥4 hours of analyzable data using the HSAT and 59.8% (70/117) of eligible patients approached obtained ≥4 hours of analyzable data.

Conclusions Our study demonstrated that HSAT was a feasible and practical technique for screening for OSA in a cognitively impaired tertiary care clinic population. As OSA is a modifiable risk factor for patients with cognitive impairment, HSAT has the potential to lead to expedited treatment for OSA, which may potentially improve health related outcomes such as cognition.

Authors/Disclosures
David R. Colelli, MSc (Sunnybrook Health Science Centre) PRESENTER	Mr. Colelli has nothing to disclose.
Sandra E. Black, MD, FAAN (Sunnybrook Health Science Center)	Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffmann-La Roche. Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Black has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai Limited . Dr. Black has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Black has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Black has received research support from Hoffmann-La Roche. The institution of Dr. Black has received research support from Biogen. The institution of Dr. Black has received research support from GE Healthcare. The institution of Dr. Black has received research support from Eli Lilly. The institution of Dr. Black has received research support from Genentech. The institution of Dr. Black has received research support from NovoNordisk. The institution of Dr. Black has received research support from UCB Biopharma. The institution of Dr. Black has received research support from Alkahest Inc. The institution of Dr. Black has received research support from University of Southern California - AHEAD 3-45 Study.
Mario Masellis, MD (Sunnybrook Health Sciences Centre)	Dr. Masellis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arkuda Therapeutics. Dr. Masellis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Masellis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alector. Dr. Masellis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Wave Life Sciences. The institution of Dr. Masellis has received research support from Canadian Institutes of Health Research. The institution of Dr. Masellis has received research support from Ontario Brain Institute. The institution of Dr. Masellis has received research support from Weston Brain Institute. The institution of Dr. Masellis has received research support from Washington University. The institution of Dr. Masellis has received research support from Alector. Dr. Masellis has received publishing royalties from a publication relating to health care.
Andrew Lim, MD (Univ Toronto / Lim and Hew Med Prof Corp)	Dr. Lim has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai Canada.
Mark I. Boulos, MD, FRCPC, CSCN(EEG), MSc (Sunnybrook Health Sciences Centre)	Dr. Boulos has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precision AQ. Dr. Boulos has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Dr. Boulos has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Techspert. Dr. Boulos has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sleep Medicine (journal). The institution of Dr. Boulos has received research support from Canadian Institutes of Health Research. The institution of Dr. Boulos has received research support from RLS Foundation. The institution of Dr. Boulos has received research support from Temerty Centre for AI Research and Education in Medicine (T-CAIREM). The institution of Dr. Boulos has received research support from Heart & Stroke Foundation of Canada. The institution of Dr. Boulos has received research support from Alternative Funding Plan from the Academic Health Sciences Centres of Ontario. The institution of Dr. Boulos has received research support from StrokeCog. The institution of Dr. Boulos has received research support from McLaughlin Centre for Molecular Medicine . The institution of Dr. Boulos has received research support from Zoll Itamar. The institution of Dr. Boulos has received research support from Toronto Dementia Research Alliance. Dr. Boulos has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Jazz Pharmaceuticals. Dr. Boulos has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Lundbeck.